Brief: Jiangsu Recbio Technology Says Got Approval Of Comparative Study Between Recov & Mrna Vaccines By FDA In Philippines
03/08/2022 09:25
Aug 3 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* APPROVAL OF COMPARATIVE STUDY BETWEEN RECOV AND MRNA
VACCINES BY
FDA IN PHILIPPINES
Source text for Eikon: ID:nHKS3tlP1J
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares